Actively Recruiting

Age: 18Years - 120Years
All Genders
Healthy Volunteers
NCT00001778

Evaluation of Patients With HAM/TSP

Led by National Institute of Neurological Disorders and Stroke (NINDS) · Updated on 2026-05-07

750

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Objective: Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus. The purpose of this protocol is to study the natural history of HAM/TSP by monitoring clinical progression of patients longitudinally. Additionally, we will attempt to define the virological and immunological changes of HAM/TSP. Study Population: Patients with HAM/TSP who fulfill World Health Organization diagnostic criteria are eligible to participate in this protocol. Asymptomatic seropositive individuals and individuals with indeterminate HTLV-1 serology are also eligible to participate. Design and Outcome Measures: A longitudinal assessment of clinical, virological and immunological progression in HAM/TSP will be accomplished through periodic testing and evaluation. Asymptomatic seropositive individuals, those with seroindeterminate HTLV-I serology and normal volunteers may serve as controls. Longitudinal standardized neurological examinations will be performed. Longitudinal samples of serum, plasma, and lymphocytes may be obtained from participants. Lumbar punctures may be performed on all participants. These samples will be used virological and immunological assays. A focus is on the relationships between the characteristics of viral infection, the immune response, and the genetic makeup.

CONDITIONS

Official Title

Evaluation of Patients With HAM/TSP

Who Can Participate

Age: 18Years - 120Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Test positive for HTLV infection (positive HTLV-1 ELISA followed by a positive Western blot)
  • Positive HTLV ELISA but a Western Blot that only partially fulfills the above criteria (seroindeterminate)
  • Have a family member/significant other who is HTLV positive, and may have been exposed to the virus
  • Healthy volunteer
  • Willingness to participate in the protocol evaluations and procedures.
Not Eligible

You will not qualify if you...

  • Unwillingness or inability to participate in the protocol evaluations and procedures
  • Presence of any medical, social, or psychiatric conditions that may affect patient safety or compliance with the protocol
  • Patients or healthy volunteers under the age of 18

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Actively Recruiting

Loading map...

Research Team

D

Daniel S Reich, M.D.

CONTACT

S

Steven Jacobson, Ph.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here